S&P 500   3,442.02 (-0.03%)
DOW   28,266.09 (-0.15%)
QQQ   284.82 (+0.14%)
AAPL   117.60 (+0.08%)
MSFT   214.72 (+0.03%)
FB   279.69 (+4.53%)
GOOGL   1,595.17 (+4.26%)
AMZN   3,185.32 (-0.99%)
TSLA   428.43 (+1.54%)
NVDA   542.23 (-0.66%)
BABA   309.54 (-0.09%)
CGC   19.51 (+3.34%)
GE   7.36 (+0.27%)
MU   53.31 (-0.41%)
AMD   80.14 (-1.74%)
T   26.65 (-0.41%)
F   7.79 (+0.65%)
ACB   4.68 (+2.63%)
GILD   60.10 (-0.78%)
NFLX   493.20 (-6.13%)
BA   165.20 (-1.22%)
BAC   24.18 (+0.17%)
DIS   125.62 (+0.54%)
S&P 500   3,442.02 (-0.03%)
DOW   28,266.09 (-0.15%)
QQQ   284.82 (+0.14%)
AAPL   117.60 (+0.08%)
MSFT   214.72 (+0.03%)
FB   279.69 (+4.53%)
GOOGL   1,595.17 (+4.26%)
AMZN   3,185.32 (-0.99%)
TSLA   428.43 (+1.54%)
NVDA   542.23 (-0.66%)
BABA   309.54 (-0.09%)
CGC   19.51 (+3.34%)
GE   7.36 (+0.27%)
MU   53.31 (-0.41%)
AMD   80.14 (-1.74%)
T   26.65 (-0.41%)
F   7.79 (+0.65%)
ACB   4.68 (+2.63%)
GILD   60.10 (-0.78%)
NFLX   493.20 (-6.13%)
BA   165.20 (-1.22%)
BAC   24.18 (+0.17%)
DIS   125.62 (+0.54%)
S&P 500   3,442.02 (-0.03%)
DOW   28,266.09 (-0.15%)
QQQ   284.82 (+0.14%)
AAPL   117.60 (+0.08%)
MSFT   214.72 (+0.03%)
FB   279.69 (+4.53%)
GOOGL   1,595.17 (+4.26%)
AMZN   3,185.32 (-0.99%)
TSLA   428.43 (+1.54%)
NVDA   542.23 (-0.66%)
BABA   309.54 (-0.09%)
CGC   19.51 (+3.34%)
GE   7.36 (+0.27%)
MU   53.31 (-0.41%)
AMD   80.14 (-1.74%)
T   26.65 (-0.41%)
F   7.79 (+0.65%)
ACB   4.68 (+2.63%)
GILD   60.10 (-0.78%)
NFLX   493.20 (-6.13%)
BA   165.20 (-1.22%)
BAC   24.18 (+0.17%)
DIS   125.62 (+0.54%)
S&P 500   3,442.02 (-0.03%)
DOW   28,266.09 (-0.15%)
QQQ   284.82 (+0.14%)
AAPL   117.60 (+0.08%)
MSFT   214.72 (+0.03%)
FB   279.69 (+4.53%)
GOOGL   1,595.17 (+4.26%)
AMZN   3,185.32 (-0.99%)
TSLA   428.43 (+1.54%)
NVDA   542.23 (-0.66%)
BABA   309.54 (-0.09%)
CGC   19.51 (+3.34%)
GE   7.36 (+0.27%)
MU   53.31 (-0.41%)
AMD   80.14 (-1.74%)
T   26.65 (-0.41%)
F   7.79 (+0.65%)
ACB   4.68 (+2.63%)
GILD   60.10 (-0.78%)
NFLX   493.20 (-6.13%)
BA   165.20 (-1.22%)
BAC   24.18 (+0.17%)
DIS   125.62 (+0.54%)
Log in
LON:XEN

Xenetic Biosciences UK Share Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume539,436 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Xenetic Biosciences plc, formerly Lipoxen plc, is a holding company engaged in development of drug and vaccine delivery systems and products in fields of protein drugs, vaccines and oncology. The Company's technology platforms include PolyXen for extending efficacy and half life of biologic drugs; ImuXen for creating new vaccines and improving existing vaccines, and OncoHist for novel mode of action drugs for oncology therapies. It has drug and vaccine programs with three products in human clinical development, such as ErepoXen, which is a long-acting formulation for treatment of anaemia in both End Stage Renal Disease patients and for those undergoing chemotherapy; OncoHist, which is a recombinant human histone H1.3 molecule in Phase I clinical trials in Russia for refractory Acute Myeloid Leukaemia and Non Hodgkin's Lymphoma, and SuliXen, which is insulin for both treatment of diabetes and for central nervous system condition. On January 17, 2012, the Company acquired SymbioTec GmbH.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
Phone+44-20-30211500
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive XEN News and Ratings via Email

Sign-up to receive the latest news and ratings for XEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xenetic Biosciences UK (LON:XEN) Frequently Asked Questions

What other stocks do shareholders of Xenetic Biosciences UK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences UK investors own include Widecells Group (WDC) and (OTC.L) (OTC).

What is Xenetic Biosciences UK's stock symbol?

Xenetic Biosciences UK trades on the London Stock Exchange (LON) under the ticker symbol "XEN."

How do I buy shares of Xenetic Biosciences UK?

Shares of XEN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How can I contact Xenetic Biosciences UK?

Xenetic Biosciences UK's mailing address is Ste 230, 99 Hayden Ave, LONDON, 2421, United Kingdom. The company can be reached via phone at +44-20-30211500.

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.